LUZP1, a novel regulator of primary cilia and the actin cytoskeleton, is a contributing factor in Townes-Brocks Syndrome

Abstract

Primary cilia are sensory organelles crucial for cell signaling during development and organ homeostasis. Cilia arise from centrosomes and their formation and function is governed by numerous factors. Through our studies on Townes-Brocks Syndrome (TBS), a rare disease linked to abnormal cilia formation in human fibroblasts, we uncovered the leucine-zipper protein LUZP1 as an interactor of truncated SALL1, a dominantly-acting protein causing the disease. Using TurboID proximity labeling and pulldowns, we show that LUZP1 associates with factors linked to centrosome and actin filaments. Here, we show that LUZP1 is a cilia regulator. It localizes around the centrioles and to actin cytoskeleton. Loss of LUZP1 reduces F-actin levels, facilitates ciliogenesis and alters Sonic Hedgehog signaling, pointing to a key role in cytoskeleton-cilia interdependency. Truncated SALL1 increases the ubiquitin proteasome-mediated degradation of LUZP1. Together with other factors, alterations in LUZP1 may be contributing to TBS etiology.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Laura Bozal-Basterra

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  2. María Gonzalez-Santamarta

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Veronica Muratore

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  4. Aitor Bermejo-Arteagabeitia

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Carolina Da Fonseca

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  6. Orhi Barroso-Gomila

    Functional Genomics, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  7. Mikel Azkargorta

    Proteomics Platform, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9115-3202
  8. Ibon Iloro

    Proteomics Platform, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Olatz Pampliega

    Department of Neurosciences, Achucarro Basque Center for Neuros, Leioa, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7924-6374
  10. Ricardo Andrade

    Analytical & High Resolution Biomedical Microscopy Core Facility, University of the Basque Country (UPV/EHU), Leioa, Spain
    Competing interests
    The authors declare that no competing interests exist.
  11. Natalia Martín-Martín

    Proteomics Unit, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  12. Tess C Branon

    Department of Biology, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alice Y Ting

    Department of Biology, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8277-5226
  14. Jose A Rodríguez

    Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Arkaitz Carracedo

    Proteomics Unit, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  16. Felix Elortza

    Proteomics Platform, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  17. James D Sutherland

    Functional Genomics, CIC bioGUNE, Derio, Spain
    For correspondence
    jsutherland@cicbiogune.es
    Competing interests
    The authors declare that no competing interests exist.
  18. Rosa Barrio

    Functional Genomics, CIC bioGUNE, Derio, Spain
    For correspondence
    rbarrio@cicbiogune.es
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9663-0669

Funding

Ministerio de Economía y Competitividad (BFU2017-84653-P)

  • Rosa Barrio

Asociacion Espanola Contra el Cancer (IDEAS175CARR)

  • Arkaitz Carracedo

Asociacion Espanola Contra el Cancer (GCTRA18006CARR)

  • Arkaitz Carracedo

La Caixa Foundation (HR17-00094)

  • Arkaitz Carracedo

European Commission (336343)

  • Arkaitz Carracedo

European Commission (PoC 754627)

  • Arkaitz Carracedo

European Commission (819242)

  • Arkaitz Carracedo

Ministerio de Economía y Competitividad (SEV-2016-0644)

  • Arkaitz Carracedo
  • Felix Elortza
  • James D Sutherland
  • Rosa Barrio

Ministerio de Economía y Competitividad (SAF2017-90900-REDT)

  • Rosa Barrio

European Commission (765445-EU)

  • Orhi Barroso-Gomila
  • James D Sutherland
  • Rosa Barrio

Basque Government (IT634-13)

  • Arkaitz Carracedo

Asociacion Espanola Contra el Cancer (POSTD19048BOZA)

  • Arkaitz Carracedo

Instituto de Salud Carlos III (PT13/0001/0027)

  • Arkaitz Carracedo

Basque Government (IKERTALDE IT1106-16)

  • Arkaitz Carracedo

Ministerio de Ciencia, Investigacion y Universidades (SAF2016-79381-R)

  • Arkaitz Carracedo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The use of human samples in this study was approved by the institutional review board (Ethics Committee at CIC bioGUNE) and appropriate informed consent was obtained from human subjects or their parents. protocol P-CBG-CBBA-2111)

Copyright

© 2020, Bozal-Basterra et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,701
    views
  • 564
    downloads
  • 31
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Laura Bozal-Basterra
  2. María Gonzalez-Santamarta
  3. Veronica Muratore
  4. Aitor Bermejo-Arteagabeitia
  5. Carolina Da Fonseca
  6. Orhi Barroso-Gomila
  7. Mikel Azkargorta
  8. Ibon Iloro
  9. Olatz Pampliega
  10. Ricardo Andrade
  11. Natalia Martín-Martín
  12. Tess C Branon
  13. Alice Y Ting
  14. Jose A Rodríguez
  15. Arkaitz Carracedo
  16. Felix Elortza
  17. James D Sutherland
  18. Rosa Barrio
(2020)
LUZP1, a novel regulator of primary cilia and the actin cytoskeleton, is a contributing factor in Townes-Brocks Syndrome
eLife 9:e55957.
https://doi.org/10.7554/eLife.55957

Share this article

https://doi.org/10.7554/eLife.55957

Further reading

    1. Cell Biology
    Satoshi Ninagawa, Masaki Matsuo ... Kazutoshi Mori
    Research Advance

    How the fate (folding versus degradation) of glycoproteins is determined in the endoplasmic reticulum (ER) is an intriguing question. Monoglucosylated glycoproteins are recognized by lectin chaperones to facilitate their folding, whereas glycoproteins exposing well-trimmed mannoses are subjected to glycoprotein ER-associated degradation (gpERAD); we have elucidated how mannoses are sequentially trimmed by EDEM family members (George et al., 2020; 2021 eLife). Although reglucosylation by UGGT was previously reported to have no effect on substrate degradation, here we directly tested this notion using cells with genetically disrupted UGGT1/2. Strikingly, the results showed that UGGT1 delayed the degradation of misfolded substrates and unstable glycoproteins including ATF6α. An experiment with a point mutant of UGGT1 indicated that the glucosylation activity of UGGT1 was required for the inhibition of early glycoprotein degradation. These and overexpression-based competition experiments suggested that the fate of glycoproteins is determined by a tug-of-war between structure formation by UGGT1 and degradation by EDEMs. We further demonstrated the physiological importance of UGGT1, since ATF6α cannot function properly without UGGT1. Thus, our work strongly suggests that UGGT1 is a central factor in ER protein quality control via the regulation of both glycoprotein folding and degradation.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.